MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Becton, Dickinson and Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Launches Family of Syringes Which Addresses Environmental Impact and Meets a Variety of Clinical Needs - BD Medical, a segment of BD (Becton, Dickinson and Company), announced the launch of the BD Emerald™ Syringe portfolio designed to meet emerging needs in medication delivery while addressing environmental impact by reducing material - BD.com
BD Launches Family of Syringes Which Addresses Environmental Impact and Meets a Variety of Clinical Needs

 

NewswireToday - /newswire/ - Franklin Lakes, NJ, United States, 2011/08/15 - BD Medical, a segment of BD (Becton, Dickinson and Company), announced the launch of the BD Emerald™ Syringe portfolio designed to meet emerging needs in medication delivery while addressing environmental impact by reducing material - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The BD Emerald Syringe portfolio includes the BD Emerald™ Conventional Syringe for general medication preparation and delivery, the BD Emerald Saf-T™ Syringe with a shielding mechanism to protect against needlesticks and the BD Emerald PRO™ Reuse Prevention Syringe featuring a passive locking system to prevent reuse.

The BD Emerald product family is designed sustainably with input from clinicians around the world. The product family is also supported by the Company’s long-standing history and commitment to developing first-class injection devices supported by clinical education programs to improve the delivery of healthcare. The BD Emerald Syringes will be manufactured at facilities in Spain, India and Brazil, utilizing sustainable manufacturing practices, including 100 percent renewable electricity for production where available. The syringes meet the International Organization and Standardization requirements, and satisfy local registration standards.

“BD recognizes that human health and a healthy environment are inseparable,” said Bill Kozy, Executive Vice President, BD. “We are committed to responsible environmental stewardship in our business conduct. The BD Emerald Syringes meet our highest standards for product quality while also reducing environmental impact by using sustainable operations practices and less material.”

The BD Emerald Syringe family offers features to prevent the spread of infection, address environmental impact, address clinical needs and meet quality standards around the world:

• BD Emerald Saf-T Syringe is designed to address the needs of healthcare workers who require protection from needlestick injuries.
• BD Emerald PRO is designed to address the needs of the developing world. The infection control issue at the forefront of healthcare delivery in these regions is preventing reuse of injection devices and the potential spread of pathogens from patient to patient.
• All syringes in the BD Emerald Syringe product family are designed to reduce medical waste effects in communities everywhere.

The BD Emerald Syringe product line builds upon BD's sustainability commitment, which has been recognized for achievements in environmental stewardship. In Newsweek’s 2010 “Green Rankings” of the 500 largest U.S. corporations, BD ranked second in the Healthcare sector and 24th overall. As part of its commitment to sustainability, BD’s worldwide headquarters and three of BD’s U.S. manufacturing sites are offsetting 100 percent of their electricity use with renewable energy through green power purchases and renewable energy credits. To learn more about environmental stewardship at BD, visit bd.com/sustainability.

About BD
BD (bd.com) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD Launches Family of Syringes Which Addresses Environmental Impact and Meets a Variety of Clinical Needs

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Barbara Kalavik - BD.com 
201-847-4209 barbara_kalavik[.]bd.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)